FDA Invites Drug Candidates Surfaced Through AI Screening

US-FEDNOTABLEGuidanceHealthcare AI

What changed

FDA guidance invites submission of drug candidates identified through high-throughput screening, in vitro models, or artificial intelligence and machine learning approaches, even absent existing clinical evidence.

Who this touches

Drug developers and research sponsors proposing candidates based on pre-clinical or AI-derived data.

Why it matters

FDA is naming AI/ML-derived pre-clinical signals as an accepted basis for submission alongside traditional screening methods.

Suggested next step — and why

Sponsors with AI-identified candidates might consider how to frame the supporting pre-clinical data package FDA asks for alongside the submission.

The clock

No date specified in this guidance passage.

Source: Primary source on file — read in the original, not from coverage.

Permanent record: this page is public forever. "When did we know?" always has a URL.

Curated nightly by Dr. Ivan Del Valle — AI governance architect, editor of The Compact. Disagree with a reading? Write ivan.delvalle@rsit.ai — every message is read, most are answered. Corrections are published, not buried. · Today's brief · Method · Reporting free forever; the desk is sustained by its data plans.